Name: MC-Val-Ala-SG3199
Brand: BOC Sciences
Rating: 5 (1 reviews)

IUPAC Name

6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-N-((S)-1-(((S)-1-((S)-7-methoxy-8-((5-(((S)-7-methoxy-2-methyl-5-oxo-5,11a-dihydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepin-8-yl)oxy)pentyl)oxy)-2-methyl-5-oxo-11,11a-dihydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepin-10(5H)-yl)-1-oxopropan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)hexanamide

InChI

InChI=1S/C51H63N7O11/c1-30(2)47(54-44(59)14-10-8-11-17-55-45(60)15-16-46(55)61)48(62)53-33(5)49(63)58-29-35-21-32(4)28-57(35)51(65)37-23-41(67-7)43(25-39(37)58)69-19-13-9-12-18-68-42-24-38-36(22-40(42)66-6)50(64)56-27-31(3)20-34(56)26-52-38/h15-16,22-28,30,33-35,47H,8-14,17-21,29H2,1-7H3,(H,53,62)(H,54,59)/t33-,34-,35-,47-/m0/s1

InChIKey

OZRQFRPAKHAVKO-MEQNFIPKSA-N

MC-Val-Ala-SG3199 is a synthetic peptide conjugate used in targeted cancer therapies. Here are some key applications of MC-Val-Ala-SG3199:

Targeted Cancer Therapy: MC-Val-Ala-SG3199 is designed to deliver cytotoxic agents directly to cancer cells, minimizing damage to healthy tissues. This approach increases the efficacy of chemotherapy by concentrating the drug’s action specifically where it’s needed. By linking SG3199, a potent warhead, to a peptide recognizer like MC-Val-Ala, this compound enhances selectivity and reduces systemic toxicity.

Immuno-oncology: In immuno-oncology, MC-Val-Ala-SG3199 can be used to modulate the immune response against tumors. By delivering the conjugate to immune cells within the tumor microenvironment, it enhances the immune cells’ ability to identify and destroy malignant cells. This can lead to improved outcomes in cancer treatment through cooperation with other immune-based therapies.

Combination Therapy Research: MC-Val-Ala-SG3199 is frequently studied in combination with other therapeutic agents to identify synergistic effects. Researchers explore how the conjugate works alongside different classes of drugs, such as checkpoint inhibitors, to amplify anti-tumor activity. Combining this peptide conjugate with other treatments could potentially lead to more effective and personalized therapeutic strategies in oncology.

Bioconjugation Technology: The use of MC-Val-Ala-SG3199 exemplifies the advancements in bioconjugation technology, allowing for precise delivery systems in drug development. Researchers study methodologies to optimize the linking of active agents to targeting moieties like peptides, thereby improving the stability and bioavailability of therapeutic compounds. This application is central to the creation of next-generation biologic drugs with enhanced capabilities.